Allogene Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
February 19 2020 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that it will
report fourth quarter and full year 2019 financial results on
Thursday, February 27, 2020 prior to the open of the market. The
announcement will be followed by a live audio webcast and
conference call at 5:30 AM Pacific Time/8:30 AM Eastern Time.
Audio Webcast The webcast will be made
available on the Company's website at www.allogene.com under
the Investors tab in the News and Events section. Following the
live audio webcast, a replay will be available on the Company's
website for approximately 30 days.
Dial-In Information Live
(U.S. / Canada): 1 (866) 940-5062 Live (International): 1
(409) 216-0618 Conference ID: 2981059
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies
for cancer. Led by a world-class management team with significant
experience in cell therapy, Allogene is developing a pipeline of
“off-the-shelf” CAR T cell therapy candidates with the goal of
delivering readily available cell therapy on-demand, more reliably,
and at greater scale to more patients. For more information, please
visit www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to develop AlloCAR T therapies for cancer and
the potential benefits of AlloCAR T therapy. Various factors may
cause differences between Allogene’s expectations and actual
results as discussed in greater detail in Allogene’s filings with
the Securities and Exchange Commission (SEC), including without
limitation in its Form 10-Q for the quarter ended September 30,
2019. Any forward-looking statements that are made in this
press release speak only as of the date of this press release.
Allogene assumes no obligation to update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Sep 2023 to Sep 2024